Search research articles
Contact Us
Filters
Showing results (501-510 of 622) with videos related to
Page
of 63
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
Eric Van Cutsem, Roberto Labianca, György Bodoky, et al.
The Lancet. Oncology
|
August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
JAMA Oncology
|
June 21, 2019
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial
Elizabeth C Smyth, Samuel Rowley, Fay H Cafferty, et al.
International Journal of Hematology
|
November 19, 2021
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
Grzegorz S Nowakowski, Wolfgang Willenbacher, Richard Greil, et al.
Scientific Reports
|
May 23, 2019
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes
Chanthirika Ragulan, Katherine Eason, Elisa Fontana, et al.
The Lancet. Gastroenterology & Hepatology
|
June 27, 2017
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
Tim Meyer, Richard Fox, Yuk Ting Ma, et al.
JCO Oncology Advances
|
May 7, 2025
Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM Study
Anderley Gordon, David Cunningham, Zayn Rajan, et al.
Leukemia & Lymphoma
|
November 10, 2017
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital
Mary Gleeson, Clare Peckitt, David Cunningham, et al.
The Lancet. Oncology
|
February 7, 2017
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial
David Cunningham, Sally P Stenning, Elizabeth C Smyth, et al.
The New England Journal of Medicine
|
October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C
Marwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
Page
of 63
Search research articles
Search
Showing results (501-510 of 622) with videos related to
Sort By:
Page
of 63
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
Eric Van Cutsem, Roberto Labianca, György Bodoky, et al.
The Lancet. Oncology
|
August 14, 2025
Health-related quality of life in patients with KRAS<sup>G12C</sup>-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, et al.
JAMA Oncology
|
June 21, 2019
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial
Elizabeth C Smyth, Samuel Rowley, Fay H Cafferty, et al.
International Journal of Hematology
|
November 19, 2021
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial
Grzegorz S Nowakowski, Wolfgang Willenbacher, Richard Greil, et al.
Scientific Reports
|
May 23, 2019
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes
Chanthirika Ragulan, Katherine Eason, Elisa Fontana, et al.
The Lancet. Gastroenterology & Hepatology
|
June 27, 2017
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
Tim Meyer, Richard Fox, Yuk Ting Ma, et al.
JCO Oncology Advances
|
May 7, 2025
Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM Study
Anderley Gordon, David Cunningham, Zayn Rajan, et al.
Leukemia & Lymphoma
|
November 10, 2017
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital
Mary Gleeson, Clare Peckitt, David Cunningham, et al.
The Lancet. Oncology
|
February 7, 2017
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial
David Cunningham, Sally P Stenning, Elizabeth C Smyth, et al.
The New England Journal of Medicine
|
October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C
Marwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
Page
of 63